Considering what has happened in the past, let’s examine various historical developments regarding Tiziana Life Sciences PLC (NASDAQ: TLSA). For the last month, shares rose 71.30% and increased 2.96% over the past five days. Stock in the company fell -5.68% in the previous quarter. The company’s performance was positive at 89.11% since the calendar year started.
Biotechnology company Tiziana Life Sciences Plc is a dual-listed company on the NASDAQ (NASDAQ: TLSA) and London Stock Exchange (LSE) that focuses on developing novel molecules to treat cancer, inflammation, and infectious diseases in humans.
Tiziana Life Sciences has reported positive results from its explorational clinical study in Brazil investigating the treatment of COVID-19 patients by nasally administering Foralumab, its proprietary human monoclonal antibody against CD3 cells. In collaboration with Harvard Medical School (Boston, USA), and INTRIALS, a Latin American CRO based in So Paulo, Brazil, the clinical study was completed.
Recent studies suggest that COVID-19 is caused by an overreaction or abnormal host response by the immune system. Weight issues are also a risk factor for COVID-19, and obesity is linked to lower circulating T-cell suppression levels. Because of higher inflammation and insulin resistance, the lungs and other organs are damaged by high levels of inflammatory cytokines, chemokines, and free radicals. Therefore, nasal treatment with Foralumab, a fully human anti-CD3 mAb, modulating the immune system and stimulating Tregs is a scientifically logical approach to COVID-19 treatment. It is also one of the only monoclonal antibodies capable of causing systemic immunity via the nasal, respiratory tract, and gut epithelial lining. These studies proved the unique delivery system of Foralumab and its safety and efficacy as a potent anti-inflammatory therapeutic.
In our lifetime, scientists are providing new insights into ways to prevent and treat diseases previously unknown. The pharmaceutical industry should offer investors huge returns if they can get their products approved by authorities.